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Introduction
Escherichia coli	O157:H7	contamination	of	human	food	products	is	a	major	concern	
for	the	beef	industry.	The	pathogens	responsible	for	outbreaks	often	originate	from	
cattle,	and	E. coli	O157:H7	can	thrive	in	healthy	cattle.	To	control	contamination	
in	the	food	chain,	it	is	essential	to	understand	how	this	pathogen	is	able	to	grow	and	
compete	with	other	bacteria	in	the	gastrointestinal	tracts	of	cattle.
Previous	studies	have	shown	that	bovine	intestinal	mucus	supports	bacterial	coloniza-
tion	and	can	selectively	influence	makeup	of	the	bacterial	population.	Intestinal	mucus	
is	made	of	mucins,	which	are	gel-forming	glycoproteins.	Mucin	molecules	contain	sialic	
acid	that	must	be	removed	by	neuraminidase	enzyme	to	allow	for	complete	degradation	
of	mucin.	E. coli	O157:H7	lacks	neuraminidase	and	should	have	little	ability	to	degrade	
the	complex	mucin	molecules.	Our	objective	was	to	evaluate	bovine	intestinal	mucus	
and	its	components	in	terms	of	their	capacity	to	support	E. coli	O157:H7	growth	in	
the	presence	or	absence	of	feces	and	to	understand	the	roles	various	enzymes	play	in		
this	process.
Experimental Procedures
Intestinal	tissues	from	freshly	harvested	cattle	were	collected	and	transported	to	our	
laboratory	in	chilled	saline.	Sections	of	the	ileum	and	colon	were	washed	with	buffer	
solution,	and	mucus	was	harvested	by	gently	scraping	the	epithelium.	We	prepared	a	
mix	of	five	selected	strains	of	Shiga	toxin-producing	E. coli	O157:H7	resistant	to	nali-
dixic	acid	(NalR)	and	added	the	mix	to	a	buffer	or	a	similar	amount	of	fecal	inoculums	
collected	from	the	rectum	of	a	steer	fed	a	high-grain	diet.	
Subsequently,	we	added	harvested	intestinal	mucus	or	individual	mucus	components	
to	the	culture	to	assess	which	components	were	most	capable	of	supporting	NalR	E. coli	
O157:H7	growth.	Intestinal	mucus	was	added	at	a	concentration	of	10	mg/mL.	Single	
components	of	mucus	(galactose,	D-galacturonic	acid,	D-gluconic	acid,	D-glucuronic	
acid,	mannose,	L-alpha-phosphatidylserine,	sialic	acid,	and	N-acetyl-D-glucosamine)	
were	added	at	the	same	concentration,	except	for	L-alpha-phosphatidylserine,	which	
was	added	at	1	mg/mL.	Initial	concentrations	of	E. coli	O157:H7	and	fecal	bacteria	in	
the	cultures	were	103	and	104	CFU/mL,	respectively.
We	also	evaluated	the	impact	of	adding	enzymes	and	enzyme	inhibitors	associated	with	
mucus	degradation	on	E. coli	O157:H7	growth.	Proteases,	endoglycosidases,	sialidases,	
or	lipases	were	added	to	the	batches	at	a	concentration	of	one	unit	per	milliliter.	Beta-
galactosidase	inhibitor	was	added	at	a	final	concentration	of	200	µM,	and	protease	
inhibitor	was	added	at	either	0.25	or	2.5	mL/g	of	E. coli	O157.
1	Funding	for	this	project	was	provided	by	the	Beef	Checkoff.
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After	0,	6,	8,	and	12	hours	of	anaerobic	incubation	at	104°F	on	a	laboratory	shaker,	
we	plated	100	µL	of	culture	at	different	dilutions	on	agar	selective	for	NalR	E. coli	
O157:H7.	After	incubating	the	plates	for	24	hours	at	98°F,	we	counted	the	NalR	E coli	
O157:H7	colonies	and	established	the	NalR	E coli	O157:H7	growth	within	the	differ-
ent	batches	(expressed	in	Log10	of	CFU/mL).
Results and Discussion
There	were	no	significant	differences	(P>0.10)	in	E. coli	O157:H7	growth	between	
mucus	derived	from	the	large	intestine	(colon)	and	small	intestine	(ileum).	The	bacteria	
increased	from	103	CFU/mL	of	culture	at	time	zero	to	107	to	108	CFU/mL	at	hour	8.
There	was	an	overall	time	effect	on	bacteria	growth	but	no	significant	difference	
between	hour	8	and	12,	which	drove	us	to	use	hour	8	as	a	point	of	comparison.	Presence	
or	absence	of	fecal	inoculums	in	the	culture	affected	(P<0.01)	E. coli	O157:H7	growth.	
The	final	concentration	of	bacteria	decreased	from	107	to	105	CFU/mL,	which	is	likely	
due	to	competition	for	nutrients	with	the	fecal	bacteria.
Figure	1	depicts	E. coli	O157:H7	growth	after	8	hours	of	anaerobic	incubation	without	
feces	but	with	whole	mucus	or	selected	components	of	mucous	as	substrates.	With	the	
exception	of	L-alpha-phosphatidylserine,	almost	all	of	the	mucus	components	tested	
increased	growth	of	the	bacteria	compared	with	the	batch	containing	only	buffer	
(P<0.05).	However,	mucus	originating	from	the	large	and	small	intestines	supported	
greater	growth	than	the	individual	mucus	fractions	(P<0.05).	Of	the	individual	mucus	
components	evaluated,	only	gluconic	acid	resulted	in	growth	similar	to	that	achieved	
with	whole	intestinal	mucus.	These	observations	suggest	E. coli	O157:H7	may	need	a	
combination	of	components	to	ensure	optimal	growth	or	that	the	bacteria	are	utilizing	
a	key	element	present	in	the	mucus	that	we	did	not	evaluate	in	this	experiment.
In	our	attempt	to	analyze	the	stimulatory	effect	of	mucus-degrading	enzymes	on	
growth	of	Shiga	toxin-producing	E. coli	O157:H7,	we	found	no	significant	differ-
ence	in	growth	of	cultures	treated	with	enzymes	or	protease	inhibitors	compared	with	
untreated	batches	(P>0.05).	Conversely,	as	illustrated	in	Figure	2,	addition	of	beta-
galactosidase	enzyme	inhibitor	increased	the	growth	of	NalR	E. coli	O157:H7	cultured	
with	either	small	or	large	intestinal	mucus	(P<0.05).	The	increase	of	growth,	instead	
of	the	expected	inhibition,	could	be	due	to	the	bacteria’s	inability	to	use	the	inhibitor	
as	a	source	of	protein.	However,	the	amount	of	inhibitor	added	to	the	culture	was	very	
small	and,	therefore,	seems	an	unlikely	explanation.	It	is	equally	possible	that	mucus	
galactosides	that	have	not	been	enzymatically	degraded	are	more	stimulatory	to	E. coli	
O157:H7	growth.	Additional	controlled	experiments	are	needed	to	further	investigate	
the	increase	of	growth	induced	by	the	beta-galactosidase	inhibitors.
Figure	3	illustrates	E. coli	O157:H7	growth	in	response	to	small	intestinal	mucus	or	
sialic	acid	substrates	in	the	presence	or	absence	of	a	fecal	inoculum.	E. coli	O157	growth	
was	significantly	lower	in	sialic	acid	than	in	mucus	(P<0.01),	indicating	the	pathogen	
has	limited	capacity	to	use	sialic	acid	as	a	substrate	for	growth.	When	fecal	inoculum	
was	added	to	the	culture	with	small	intestinal	mucus,	there	was	a	significant	decrease	
in	E. coli	growth	compared	with	the	same	culture	without	feces.	This	again	suggests	the	
bacteria	are	competing	for	nutrients.	However,	E. coli	O157:H7	growth	increased	when	
fecal	inoculum	was	added	to	the	culture	containing	sialic	acid.	Bacteria	present	in	feces	
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may	have	the	ability	to	degrade	sialic	acid,	thus	allowing	E. coli	O157:H7	to	use	the	
intermediates	or	end	products	of	the	degradation	as	a	substrate	for	growth.	
Cattle	fed	distillers	grains	have	been	shown	to	have	an	increase	in	E. coli	O157	shed-
ding,	and	distillers	grains	contain	a	substantial	proportion	of	yeast,	which	has	a	high	
sialic	acid	content	(3%	of	dry	weight).	It	is	possible	that	sialic	acid	or	other	glycoprotein	
constituents	of	distillers	grains	are	the	active	components	that	stimulate	proliferation	of	
E. coli	O157:H7	in	cattle	fed	distillers	grains.
Implications
This	study	offers	insight	regarding	the	potential	of	intestinal	mucus	and	its	components	
to	promote	E. coli	O157:H7	growth	in	cattle.	Further	investigations	are	needed	to	
establish	whether	one	of	these	components	could	inhibit,	or	at	least	regulate,	the	prolif-
eration	of	important	foodborne	pathogens.	
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Figure 1. Growth of nalidixic acid-resistant Escherichia coli O157:H7 on small intestinal 
mucus, large intestinal mucus, or components of mucus after 8 hours of incubation.
Cultures	were	inoculated	with	103	CFU/mL	of	nalidixic	acid-resistant	E. coli O157:H7	prior	
to	incubation.
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Figure 2. Growth of nalidixic acid-resistant Escherichia coli O157:H7 with small or large 
intestinal mucus in the presence and absence of beta-galactosidase enzyme inhibitor.
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Figure 3. Growth of nalidixic acid-resistant Escherichia coli O157:H7 in response to small 
intestinal mucus or sialic acid as substrate in the presence and absence of a fecal inoculum.  
